Overview

The purpose of this study is to determine if the combination of the three anti-cancer drugs carboplatin, paclitaxel, and ramucirumab is helpful in shrinking tumors or delaying tumor growth in participants with non-small cell lung cancer. This study will also assess whether it is safe to combine these drugs.

Eligibility

Inclusion Criteria:

• Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older
• Prior exposure to 4-6 cycles of Pem/Carbo/Pembro and PD after at least 18 weeks of maintenance Pemetrexed, Pembrolizumab or the combination of the two.
• PS 0-1

Exclusion Criteria:

• Presence of a driver mutation that is susceptible to targeted therapy
• Other active invasive malignancy requiring ongoing therapy
• Grade 2 or higher sensory neuropathy
• Evidence of untreated brain metastases
• History of bleeding diatheses or recent, antecedent hemoptysis (> 1/2 teaspoon in prior 2 months)